ESMO 2019 | Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, discusses the results of the phase 3 KEYNOTE-522 study of pembrolizumab and chemotherapy vs. placebo and chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs. placebo as adjuvant treatment for early triple-negative breast cancer. Giuseppe Curigliano, MD, PhD, from the European Institute of Oncology, Milan, Italy, then explains on the impacts of these results.